Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Top Story

Wilex plummets on Rencarex miss

October 17, 2012 12:45 AM UTC

Wilex AG (Xetra:WL6) fell EUR 2.40 (62%) to EUR 1.50 on Tuesday after Rencarex girentuximab missed the primary endpoint of improving median disease-free survival (DFS) vs. placebo in the Phase III ARISER trial to treat clear cell renal cell carcinoma (RCC). ARISER was evaluating once-weekly Rencarex for 24 weeks following complete or partial surgical removal of the affected kidney in patients with no detectable metastases. Rencarex is a chimeric mAb against carbonic anhydrase IX (CAIX). ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article